This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brenner, B. G.
Right arrow Articles by Wainberg, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brenner, B. G.
Right arrow Articles by Wainberg, M. A.

 Previous Article  |  Next Article 

Journal of Virology, February 2002, p. 1753-1761, Vol. 76, No. 4
0022-538X/01/$04.00+0     DOI: 10.1128/JVI.76.4.1753-1761.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection

Bluma G. Brenner,1 Jean-Pierre Routy,2 Marco Petrella,1 Daniela Moisi,1 Maureen Oliveira,1 Mervi Detorio,1 Bonnie Spira,1 Vidal Essabag,1 Brian Conway,3 Richard Lalonde,2 Rafick-Pierre Sekaly,4 and Mark A. Wainberg1*

McGill University AIDS Centre, Jewish General Hospital,1 McGill University Health Centre,,2 Université de Montréal, Montreal, Quebec,,4 University of British Columbia, Vancouver, British Columbia, Canada3

Received 5 July 2001/ Accepted 31 October 2001

This study examines the persistence and fitness of multidrug-resistant (MDR) viruses acquired during primary human immunodeficiency virus infection (PHI). In four individuals, MDR infections persisted over the entire study period, ranging from 36 weeks to 5 years, in the absence of antiretroviral therapy. In stark contrast, identified source partners in two cases showed expected outgrowth of wild-type (WT) virus within 12 weeks of treatment interruption. In the first PHI case, triple-class MDR resulted in low plasma viremia (1.6 to 3 log copies/ml) over time compared with mean values obtained for an untreated PHI group harboring WT infections (4.1 to 4.3 log copies/ml). Increasing viremia in PHI patient 1 at week 52 was associated with the de novo emergence of a protease inhibitor-resistant variant through a recombination event involving the original MDR virus. MDR infections in two other untreated PHI patients yielded viremia levels typical of the untreated WT group. A fourth patient's MDR infection yielded low viremia (<50 to 500 copies/ml) for 5 years despite his having phenotypic resistance to all antiretroviral drugs in his treatment regimen. In two of these PHI cases, a rebound to higher levels of plasma viremia only occurred when the M184V mutation in reverse transcriptase could no longer be detected and, in a third case, nondetection of M184V was associated with an inability to isolate virus. To further evaluate the fitness of MDR variants acquired in PHI, MDR and corresponding WT viruses were isolated from index and source partners, respectively. Although MDR viral infectivity (50% tissue culture infective dose) was comparable to that observed for WT viruses, MDR infections in each case demonstrated 2-fold and 13- to 23-fold reductions in p24 antigen and reverse transcriptase enzymatic activity, respectively. In dual-infection competition assays, MDR viruses consistently demonstrated a marked replicative disadvantage compared with WT virus. These results indicate that MDR viruses that are generated following PHI can establish persistent infections as dominant quasispecies despite their impaired replicative competence.

* Corresponding author. Mailing address: McGill University AIDS Centre, Lady Davis Institute-Jewish General Hospital, 3755 Cote Ste-Catherine Rd., Montreal, Quebec, Canada H3T 1E2. Phone: (514) 340-8260. Fax: (514) 340-7537. E-mail: mwainb1{at}po-box.mcgill.ca.

Journal of Virology, February 2002, p. 1753-1761, Vol. 76, No. 4
0022-538X/01/$04.00+0     DOI: 10.1128/JVI.76.4.1753-1761.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kolli, M., Stawiski, E., Chappey, C., Schiffer, C. A. (2009). Human Immunodeficiency Virus Type 1 Protease-Correlated Cleavage Site Mutations Enhance Inhibitor Resistance. J. Virol. 83: 11027-11042 [Abstract] [Full Text]  
  • Bracciale, L., Colafigli, M., Zazzi, M., Corsi, P., Meraviglia, P., Micheli, V., Maserati, R., Gianotti, N., Penco, G., Setti, M., Di Giambenedetto, S., Butini, L., Vivarelli, A., Trezzi, M., De Luca, A. (2009). Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. J Antimicrob Chemother 64: 607-615 [Abstract] [Full Text]  
  • Taylor, S., Jayasuriya, A., Smit, E. (2009). Using HIV resistance tests in clinical practice. J Antimicrob Chemother 64: 218-222 [Abstract] [Full Text]  
  • Ntemgwa, M. L., Toni, T. d., Brenner, B. G., Oliveira, M., Asahchop, E. L., Moisi, D., Wainberg, M. A. (2009). Nucleoside and Nucleotide Analogs Select in Culture for Different Patterns of Drug Resistance in Human Immunodeficiency Virus Types 1 and 2. Antimicrob. Agents Chemother. 53: 708-715 [Abstract] [Full Text]  
  • Little, S. J., Frost, S. D. W., Wong, J. K., Smith, D. M., Pond, S. L. K., Ignacio, C. C., Parkin, N. T., Petropoulos, C. J., Richman, D. D. (2008). Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection. J. Virol. 82: 5510-5518 [Abstract] [Full Text]  
  • Poon, A. F. Y., Kosakovsky Pond, S. L., Richman, D. D., Frost, S. D. W. (2007). Mapping Protease Inhibitor Resistance to Human Immunodeficiency Virus Type 1 Sequence Polymorphisms within Patients. J. Virol. 81: 13598-13607 [Abstract] [Full Text]  
  • Dykes, C., Demeter, L. M. (2007). Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev. 20: 550-578 [Abstract] [Full Text]  
  • Taiwo, B. O., Murphy, R. (2007). Transmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings. J Int Assoc Physicians AIDS Care (Chic Ill) 6: 188-197 [Abstract]  
  • Booth, C. L., Geretti, A. M. (2007). Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 59: 1047-1056 [Abstract] [Full Text]  
  • Cong, M.-e., Heneine, W., Garcia-Lerma, J. G. (2007). The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational Interactions. J. Virol. 81: 3037-3041 [Abstract] [Full Text]  
  • Booth, C. L., Garcia-Diaz, A. M., Youle, M. S., Johnson, M. A., Phillips, A., Geretti, A. M. (2007). Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 59: 517-524 [Abstract] [Full Text]  
  • Ntemgwa, M., Brenner, B. G., Oliveira, M., Moisi, D., Wainberg, M. A. (2007). Natural Polymorphisms in the Human Immunodeficiency Virus Type 2 Protease Can Accelerate Time to Development of Resistance to Protease Inhibitors. Antimicrob. Agents Chemother. 51: 604-610 [Abstract] [Full Text]  
  • Garcia-Lerma, J. G. (2005). Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons. J Antimicrob Chemother 56: 265-269 [Abstract] [Full Text]  
  • Bouchonnet, F., Dam, E., Mammano, F., de Soultrait, V., Hennere, G., Benech, H., Clavel, F., Hance, A. J. (2005). Quantification of the Effects on Viral DNA Synthesis of Reverse Transcriptase Mutations Conferring Human Immunodeficiency Virus Type 1 Resistance to Nucleoside Analogues. J. Virol. 79: 812-822 [Abstract] [Full Text]  
  • Petrella, M., Oliveira, M., Moisi, D., Detorio, M., Brenner, B. G., Wainberg, M. A. (2004). Differential Maintenance of the M184V Substitution in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 by Various Nucleoside Antiretroviral Agents in Tissue Culture. Antimicrob. Agents Chemother. 48: 4189-4194 [Abstract] [Full Text]  
  • Tamiya, S., Mardy, S., Kavlick, M. F., Yoshimura, K., Mistuya, H. (2004). Amino Acid Insertions near Gag Cleavage Sites Restore the Otherwise Compromised Replication of Human Immunodeficiency Virus Type 1 Variants Resistant to Protease Inhibitors. J. Virol. 78: 12030-12040 [Abstract] [Full Text]  
  • Marozsan, A. J., Fraundorf, E., Abraha, A., Baird, H., Moore, D., Troyer, R., Nankja, I., Arts, E. J. (2004). Relationships between Infectious Titer, Capsid Protein Levels, and Reverse Transcriptase Activities of Diverse Human Immunodeficiency Virus Type 1 Isolates. J. Virol. 78: 11130-11141 [Abstract] [Full Text]  
  • Garcia-Lerma, J. G., MacInnes, H., Bennett, D., Weinstock, H., Heneine, W. (2004). Transmitted Human Immunodeficiency Virus Type 1 Carrying the D67N or K219Q/E Mutation Evolves Rapidly to Zidovudine Resistance In Vitro and Shows a High Replicative Fitness in the Presence of Zidovudine. J. Virol. 78: 7545-7552 [Abstract] [Full Text]  
  • Scott, P., Arnold, E., Evans, B., Pozniak, A., Moyle, G., Shahmenesh, M., White, D., Shirley, J., Cane, P., Pillay, D. (2004). Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J Antimicrob Chemother 53: 469-473 [Abstract] [Full Text]  
  • Bulgheroni, E., Citterio, P., Croce, F., Lo Cicero, M., Vigano, O., Soster, F., Chou, T.-C., Galli, M., Rusconi, S. (2004). Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. J Antimicrob Chemother 53: 464-468 [Abstract] [Full Text]  
  • Turner, D., Brenner, B., Wainberg, M. A. (2004). Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1. J Antimicrob Chemother 53: 53-57 [Abstract] [Full Text]  
  • Russell, R. S., Roldan, A., Detorio, M., Hu, J., Wainberg, M. A., Liang, C. (2003). Effects of a Single Amino Acid Substitution within the p2 Region of Human Immunodeficiency Virus Type 1 on Packaging of Spliced Viral RNA. J. Virol. 77: 12986-12995 [Abstract] [Full Text]  
  • Weber, J., Rangel, H. R., Chakraborty, B., Tadele, M., Martinez, M. A., Martinez-Picado, J., Marotta, M. L., Mirza, M., Ruiz, L., Clotet, B., Wrin, T., Petropoulos, C. J., Quinones-Mateu, M. E. (2003). A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. J. Gen. Virol. 84: 2217-2228 [Abstract] [Full Text]  
  • Simon, V., Padte, N., Murray, D., Vanderhoeven, J., Wrin, T., Parkin, N., Di Mascio, M., Markowitz, M. (2003). Infectivity and Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1 Variants Isolated during Primary Infection. J. Virol. 77: 7736-7745 [Abstract] [Full Text]  
  • Diallo, K., Brenner, B., Oliveira, M., Moisi, D., Detorio, M., Gotte, M., Wainberg, M. A. (2003). The M184V Substitution in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Delays the Development of Resistance to Amprenavir and Efavirenz in Subtype B and C Clinical Isolates. Antimicrob. Agents Chemother. 47: 2376-2379 [Abstract] [Full Text]  
  • Quinones-Mateu, M. E., Tadele, M., Parera, M., Mas, A., Weber, J., Rangel, H. R., Chakraborty, B., Clotet, B., Domingo, E., Menendez-Arias, L., Martinez, M. A. (2002). Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation. J. Virol. 76: 10546-10552 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»